Found 214 clinical trials
A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer (POD1UM-304) (POD1UM-304)
The purpose of this study is to assess the efficacy and safety of platinum-based chemotherapy with or without INCMGA00012 in participants with metastatic squamous and nonsquamous non-small cell
- 24 views
- 23 Oct, 2022
- 120 locations
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) (POD1UM-204)
platinum-based chemotherapy. retifanlimab will be administered as monotherapy or in combination with other immunotherapy or targeted agents.
- 59 views
- 25 Oct, 2022
- 53 locations
Randomized, Open Label Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated Metastatic Non- Squamous Non-Small Cell Lung Cancer Patients With CEACAM5 Positive Tumors (CARMEN-LC03)
with standard-of-care platinum-based chemotherapy and an immune checkpoint inhibitor (ICI). The primary objective is to determine whether tusamitamab ravtansine improves the overall survival
- 132 views
- 17 Nov, 2022
- 5 locations
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy
platinum-based chemotherapy.
- 92 views
- 10 May, 2022
- 24 locations
A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)
docetaxel in patients with advanced non-squamous NSCLC who have previously experienced radiographic disease progression on or after treatment with platinum-based chemotherapy in combination with CIT.
- 543 views
- 04 May, 2022
- 143 locations
A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non–Small Cell Lung Cancer.
The purpose of this study is to assess the efficacy and safety of platinum-based chemotherapy with or without INCMGA00012 in participants with metastatic squamous and nonsquamous non–small
- 42 views
- 10 May, 2022
- 1 location
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma (516-003)
following: Whether or not patients were previously treated with or were ineligible for platinum-based chemotherapy Whether or not patients were previously treated with a
- 86 views
- 02 Jun, 2021
- 1 location
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (MARIPOSA-2)
The purpose of this study is to assess the efficacy of lazertinib, amivantamab, carboplatin, and pemetrexed (LACP) and amivantamab, carboplatin and pemetrexed (ACP) compared with carboplatin and pemetrexed (CP), respectively, in participants with locally advanced or metastatic epidermal growth factor receptor (EGFR) Exon 19del or Exon 21 L858R substitution non-small …
- 18 views
- 23 Oct, 2022
- 217 locations
A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy: LATIFY (LATIFY)
progression on prior anti-PD-(L)1 therapy and platinum-based chemotherapy.
- 0 views
- 27 Oct, 2022
- 1 location
A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O). (DUO-O)
This is a Phase III randomised, double-blind, multi-centre study to evaluate the efficacy and safety of durvalumab in combination with standard of care platinum based chemotherapy and
- 119 views
- 24 Oct, 2022
- 20 locations